FDA
-
-
-
-
-
-
-
Mineralys repurchases lorundrostat royalty rights for up to $300 million
-
-
-
-
-
-
-
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
-
-
-
-
-
-
-
Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025
-
-
-
-
-
-
-
Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need
-
-
-
-
-
-
-
Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria
-
-
-
-
-
-
-
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual
-
331,813 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

